A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness


Authors: Sabeena Ahmed 1, Mohammad Mahbubul Karim 1, Allen G Ross 1, Mohammad Sharif Hossain 1, John D Clemens 1, Mariya Kibtiya Sumiya 1, Ching Swe Phru 1, Mustafizur Rahman 1, Khalequ Zaman 1, Jyoti Somani 2, Rubina Yasmin 3, Mohammad Abul Hasnat 4, Ahmedul Kabir 5, Asma Binte Aziz 1, Wasif Ali Khan 6 Abstract Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial […]

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines


Authors: Andrew Bryant, MSc,1,* Theresa A. Lawrie, MBBCh, PhD,2 Therese Dowswell, PhD,2 Edmund J. Fordham, PhD,2 Scott Mitchell, MBChB, MRCS,3 Sarah R. Hill, PhD,1 and Tony C. Tham, MD, FRCP4 Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed […]

Critics Fault Henry Ford Hydroxychloroquine Study Methodology, Conclusion


Authors: by Alex McLenon | July 15, 2020 One critic says the study, which found the drug led to fewer COVID-19 deaths, did not used a randomized trial and patients not administered the drug were more likely to die anyway. A recent Henry Ford Health System study finding COVID-19 patients treated with hydroxycloroquine were less likely to die from the virus is drawing skepticism […]

An Update: Is hydroxychloroquine effective for COVID-19?


Authors: Medically reviewed by Drugs.com. Last updated on Feb 2, 2021. Multiple studies provide data that hydroxychloroquine (brand name: Plaquenil) does not provide a medical benefit for hospitalized patients with COVID-19. Hydroxychloroquine, an FDA-approved prescription drug used for malaria, rheumatoid arthritis and lupus erythematosus, has been suggested as a possible treatment or preventive for COVID-19 based […]

Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence


Authors: Myron S. Cohen, M.D. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has generated a worldwide pandemic. The interruption of its spread depends on a combination of pharmacologic and nonpharmacologic interventions. Initial SARS-CoV-2 prevention includes social distancing, the use of face masks, environmental hygiene, and hand washing.1 Although […]

90% Of Patients Treated With Experimental Israeli COVID Drug Discharged Within 5 Days


Authors: BY TYLER DURDEN Finally, it looks like the world might be on the verge of obtaining a therapeutic drug that’s actually effective at helping patients infected with COVID. But you probably won’t hear anything about this latest breakthrough from the American media, which covered the race for a vaccine with breathless enthusiasm. According to […]

The complement system in COVID-19: friend and foe?


Authors: Anuja Java,1 Anthony J. Apicelli,2 M. Kathryn Liszewski,3 Ariella Coler-Reilly,3 John P. Atkinson,3 Alfred H.J. Kim,3 and Hrishikesh S. Kulkarni4 Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic and a disruptive health crisis. COVID-19–related morbidity and mortality have been attributed to an exaggerated immune response. The role of complement […]

Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection


Authors: Lina Ma1, View ORCID ProfileSanjaya K. Sahu1, View ORCID ProfileMarlene Cano1, Vasanthan Kuppuswamy2, Jamal Bajwa1,3, View ORCID ProfileJa’Nia McPhatter1,4 Complement activation has been implicated in the pathogenesis of severe SARS-CoV-2 infection. However, it remains to be determined whether increased complement activation is a broad indicator of critical illness (and thus, no different in COVID-19). It is also unclear which […]

ADVERSE EFFECTS OF MESSENGER RNA VACCINES: An Evidence Review from the Penn Medicine Center for Evidence-based Practice


Authors: Project director: Nikhil K. Mull, MD (CEP), Lead analyst: Matthew D. Mitchell, PhD (CEP), Clinical review: Patrick J. Brennan, MD. (CMO) EVIDENCE SUMMARY: 1. There are no specific guidelines for use of messenger RNA (mRNA) vaccines or contraindications to mRNA vaccines.2. No large trials of any mRNA vaccine have been completed yet.3. The only […]

Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ)


Authors: Milind Desai, M. D, Suma Thomas Principal Investigators: The Cleveland Clinic A Clinical Trail to see whether ascorbic acid and zinc gluconate which has limited side effect profile and is readily available over the counter can decrease the duration of symptoms seen in patients with new diagnosis of COVID-2019. A secondary purpose is to […]